Lyka Labs Ltd

LYKALABS
Health CarePharmaceuticals
SmallcapWith a market cap of ₹670 cr, stock is ranked 1,189
High RiskStock is 3.69x as volatile as Nifty
221.9011.65 (-4.99%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹670 cr, stock is ranked 1,189
High RiskStock is 3.69x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
-58.01
PB RatioPB Ratio
-27.47
Dividend YieldDiv. Yield
Sector PESector PE
37.99
Sector PBSector PB
5.06
Sector Div YldSctr Div Yld
0.68%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Lyka Labs Limited is a pharmaceutical products and services provider. The Company is primarily engaged in formulation and manufacturing lyophilized products.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

See Plans

Financial TrendFinancial statements 

201820192020202165.3972.8766.3387.81-17.27-5.56-60.54-11.55
Revenue
Profit
Loss
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Decreased Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has decreased by 1.38%

See detailed holdings

Recent EventsAll events 

Financial Result Updates 
Announced OnJan 20, 2022

Lyka Labs Limited has submitted to the Exchange, the financial results for the period ended December 31, 2021. | Download

Lyka Labs Limited has submitted to the Exchange, the financial results for the period ended December 31, 2021. | Download

Outcome of Board Meeting 
Announced OnJan 20, 2022

Lyka Labs Limited has informed the Exchange regarding Board meeting held on January 20, 2022. | Download

Lyka Labs Limited has informed the Exchange regarding Board meeting held on January 20, 2022. | Download

Corrigendum 
Announced OnJan 20, 2022

Arihant Capital Markets Limited has submitted to the Exchange a copy of public announcement cum Corrigendum to Detailed Public Statement (DPS) for the attention of the equity shareholders of the Company. | Download

Arihant Capital Markets Limited has submitted to the Exchange a copy of public announcement cum Corrigendum to Detailed Public Statement (DPS) for the attention of the equity shareholders of the Company. | Download

See all events